Jim Eubanks, PhD, national director of medical affairs at Octave, provided thoughts on the company’s $10 million grant from The Michael J. Fox Foundation for Parkinson’s Research and highlighted the importance of awareness for movement disorders like Parkinson disease.
Despite additional information submitted, the FDA continues to impose a clinical hold on Entrada Therapeutics' ENTR-601-44 for the potential treatment of Duchenne muscular dystrophy.
The chief executive officer at Parkinson & Movement Disorder Alliance and the president at PD Avengers discussed the importance of awareness in movement disorders and the challenges that patients still face in getting access to treatments for improved quality of life. [WATCH TIME: 12 minutes
Heather Synder, PhD, vice president of medical and scientific relations at the Alzheimer’s Association, gave thoughts on the recently concluded CTAD conference and how the organization plans to carry the positive momentum in the field.
The professor of neurology at the University of Toronto provided insight on several prominent targets in the brain for deep brain stimulation, including emerging ones that may not gain as much attention. [WATCH TIME: 3 minutes]
The director of the headache section at Cleveland Clinic’s Neurological Institute provided thoughts on how recent advances have propelled migraine care, treatment possibilities behind prevention, and emerging research targets.
In a new announcement, the FDA warns patients to immediately seek out medical attention if unexplained rash, fever, or swollen lymph nodes develop when using the antiseizure medications levetiracetam and clobazam.
The associate professor in the department of neurology at Mayo Clinic College of Medicine talked about findings from a real-world study assessing eptinezumab among patients with chronic migraine which was presented at the AHS Scottsdale Headache Symposium 2023. [WATCH TIME: 4 minutes]
Alvaro Pascual-Leone, MD, PhD, director of the Berenson-Allen Center for Noninvasive Brain Stimulation at Beth Israel Deaconess Medical Center, provided commentary on the ways Alzheimer disease treatment has changed and how clinicians will need to adapt in the coming years.
As part of our monthly clinician spotlight, NeurologyLive® highlighted epilepsy expert Patricia C. Dugan, MD, director of the epilepsy fellowship program at NYU Langone Health.
The interim chief of pediatric neurology at Stanford Medicine Children’s Health discussed progress in preventing seizures among patients with epilepsy, the potential for gene-targeted therapies, and the importance of localizing where seizures are coming from. [WATCH TIME: 5 minutes]
The odds of making a specific diagnosis nearly doubled when the patient headache questionnaire was employed, resulting in more accurate identification and subsequent treatment of migraine cases.
Across 31 studies of patients with NMOSD, more than half of the patients included reported having sleep disturbances associated with their condition.
Neurona Therapeutics’ NRTX-1001, a regenerative neural cell therapy derived from human stem cells, showed promise in potentially suppressing seizures in patients with drug-resistant mesial temporal lobe epilepsy.
A panel of experts provide commentary on a range of topics regarding the integration of biosimilars in the management of multiple sclerosis, including the supporting data behind these agents and how the clinical community can adapt.
Review the latest peer-reviewed articles dedicated to the multidisciplinary management of multiple sclerosis published in the International Journal of MS Care.
Here's some of what is coming soon to NeurologyLive® this week.
Significant associations between higher third-trimester ASM concentrations with poorer adaptive and behavior outcomes were seen on several assessments, including the Adaptive Behavior Assessment System, Third Edition.
Despite the diagnosis of MS improving, misdiagnosis remains a challenge, pointing to the need for proper differential diagnosis and mimic identification.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is general neurology.
The study added to the evidence base for recommending adherence to treatment with disease-modifying therapies in clinical practice, a key element for reducing moderate or severe relapse rate.
With the first approved biosimilar entering the US treatment market, the time for clinicians to understand the coming era of therapies is now.
Neurology News Network for the week ending November 25, 2023. [WATCH TIME: 4 minutes
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 24, 2023.
Apart from the small pump system, which was preferred by the patients, the study found no clear advantage of levodopa-entacapone-carbidopa to levodopa-carbidopa intestinal gel.
The effect of gaslighting on patients can result in serious harms, and although it is potentially common in the MS care continuum, whether it is deliberate or an institutional problem, it must be called out by providers.
We are closer than ever to individualized management of MS, and keeping up with the rapidly changing pace of MS care is challenging even for an MS specialist.
Rebecca Whitney, associate director of Programs and Community Support at SRNA and mother of child with a rare neuroimmune disorder, provided thoughts on the importance of caregivers and the role they play in everyday life.
The associate professor of clinical neurology at University of Miami Miller School of Medicine discussed the implications of findings from a recent post hoc analysis on midazolam and the need for inclusive research in assessing the efficacy of seizure rescue treatments. [WATCH TIME: 3 minutes]
In a recently published study, investigators have identified a part of the brain that may be associated with breathing failure following a seizure in patients with severe epilepsy that cannot be managed with treatment.
